Plus Therapeutics Shares Surge on Analyst Upgrade and Insider Buying

Shares of Plus Therapeutics experienced significant upward momentum in today’s trading session, propelled by a combination of revised analyst projections and substantial insider acquisitions. The stock advanced as much as 14.79% since market open, demonstrating unusually strong market activity.

The rally received substantial support from Ascendiant Capital, where analyst Edward Woo maintained his “Buy” recommendation while increasing the price target from $20.50 to $21.00—representing a 2.44% upward adjustment. This vote of confidence wasn’t isolated within the financial community:

• D. Boral Capital continues to endorse the equity with a “Buy” rating and maintains a $5.00 price objective
• Maxim Group sustains its “Buy” stance despite reducing its target from $4.00 to $3.00
• The collective assessment from four brokerage firms indicates an... Read more...